We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Proteomics Platform Identifies Proteins in Blood to Give Cancer Warning 7 Years before Diagnosis

By LabMedica International staff writers
Posted on 11 Jun 2024
Print article
Image: The Olink Explore platform can identify proteins in blood that may provide a 7-year warning for various cancers (Photo courtesy of Olink Holding)
Image: The Olink Explore platform can identify proteins in blood that may provide a 7-year warning for various cancers (Photo courtesy of Olink Holding)

To improve cancer survival rates, it's crucial to understand the disease during its initial stages. Research involving data from thousands of cancer patients has uncovered exciting findings about how blood proteins can influence cancer risk, highlighting the need for further investigation to determine which proteins could be effectively utilized for prevention. Researchers have now employed a cutting-edge proteomics platform to identify blood proteins that could potentially provide a seven-year advance warning for various types of cancer. Their study findings underscore the significant potential of proteomics to transform cancer detection, enabling earlier interventions that could lead to improved treatment success and possibly even prevention.

In this groundbreaking study recently published in Nature Communications, the researchers used Olink Holding AB’s (Uppsala, Sweden) next-generation Olink Explore proteomics platform to examine blood samples from over 44,000 individuals. They successfully identified 371 proteins associated with 19 different types of cancer, including 107 proteins that could be detected in individuals up to seven years before a cancer diagnosis was made. The platform's scalability and precision allowed the researchers to conduct detailed analyses of a vast array of proteins across a large number of samples, revealing vital insights into the complex protein dynamics of the human body. Although these results are highly promising for the advancement of cancer management, the researchers have stressed the importance of further studies. It is essential to delve deeper into the roles these proteins play in the onset of cancer and to identify the most dependable proteins for future diagnostic tests.

“This breakthrough research, enabled by the Olink platform and the UKB Pharma Proteomics project, offers a glimpse into a future where early cancer detection and preventive intervention becomes a reality,” said Carl Raimond, President, Olink. “With continued research and development, discoveries such as these have the potential to transform how disease is diagnosed, treated, and prevented.” 

Related Links:
Olink Holding AB

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: The new DxC 500i Clinical Analyzer is an integrated clinical chemistry and immunoassay analyzer (Photo courtesy of Beckman Coulter Diagnostics)

Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability

As global healthcare systems increasingly shift towards networked laboratory operational models to enhance efficiency and patient access, there is a greater need for innovative solutions tailored to the... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Pathology

view channel
Image: Color-enhanced scanning electron micrograph showing Salmonella Typhimurium (red) invading cultured human cells (Photo courtesy of Rocky Mountain Laboratories, NIAID, NIH)

AI Identifies Drug-Resistant Typhoid-Like Infection from Microscopy Images within Hours

Antimicrobial resistance is becoming a serious global health concern, making many infections increasingly difficult to treat and limiting available treatment options. This escalation in resistance raises... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.